v3.26.1
Segment Reporting
 9 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Segment Reporting

 

10.Segment Reporting

 

The Company operates as one operating segment with a focus on its efforts to develop drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. The Company's CEO, as the chief operating decision maker, manages and allocates resources to the operations of the Company based on the line items included within these condensed financial statements and segment performance is evaluated based on net loss. This enables the CEO to assess the overall level of available resources and determine how best to deploy these resources across functions, clinical trials, and development projects in line with the long-term company-wide strategic goals. The measurement of segment assets is reported on the condensed balance sheet as total assets. All of the Company’s tangible assets are held in the United States.

 

The following table presents selected financial information with respect to the Company’s single operating segment and its significant segment approximated expenses for the nine months ended March 31, 2026 and 2025:

 

          
   Nine months ended   Nine months ended 
   March 31, 2026   March 31, 2025 
         
Clinical studies  $6,602,000   $4,097,000 
Clinical teams   3,255,000    2,968,000 
Chemistry, manufacturing and controls   142,000    726,000 
Other research and development expenses   384,000    251,000 
General and administrative expenses   6,377,000    6,189,000 
Amortization of intangible assets   172,000    172,000 
Other income, net   (505,000)   (350,000)
Net loss  $(16,427,000)  $(14,053,000)